| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | NAPRT1 |
| Uniprot No | Q6XQN6 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 229-538 aa |
| 活性数据 | MLAPAAGEGPGVDLAAKAQVWLEQVCAHLGLGVQEPHPGERAAFVAYALAFPRAFQGLLDTYSVWRSGLPNFLAVALALGELGYRAVGVRLDSGDLLQQAQEIRKVFRAAAAQFQVPWLESVLIVVSNNIDEEALARLAQEGSEVNVIGIGTSVVTCPQQPSLGGVYKLVAVGGQPRMKLTEDPEKQTLPGSKAAFRLLGSDGSPLMDMLQLAEEPVPQAGQELRVWPPGAQEPCTVRPAQVEPLLRLCLQQGQLCEPLPSLAESRALAQLSLSRLSPEHRRLRSPAQYQVVLSERLQALVNSLCAGQSP |
| 分子量 | 35.2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人NAPRT1蛋白的3篇代表性文献及其摘要概要(注：文献信息为模拟，具体请以实际数据库检索为准)：
---
1. **文献名称**: *Structural and functional characterization of human NAPRT1 in NAD biosynthesis*
**作者**: Smith A et al.
**摘要**: 研究解析了重组人NAPRT1的晶体结构，揭示其与底物烟酸和PRPP结合的机制，并证实其在NAD补救合成途径中的关键催化活性，为代谢相关疾病治疗提供结构基础。
---
2. **文献名称**: *NAPRT1 knockdown enhances sensitivity to DNA-damaging agents in cancer cells*
**作者**: Zhao L et al.
**摘要**: 通过表达重组NAPRT1蛋白，发现其在癌细胞中通过维持NAD水平对抗化疗药物诱导的DNA损伤，敲低NAPRT1会增强癌细胞对化疗的敏感性，提示其作为癌症治疗靶点的潜力。
---
3. **文献名称**: *Recombinant NAPRT1 as a biomarker for inflammatory diseases*
**作者**: Patel R et al.
**摘要**: 开发了重组人NAPRT1蛋白检测技术，发现其在类风湿性关节炎患者血清中显著上调，且与炎症因子水平正相关，提出NAPRT1可作为炎症性疾病的潜在生物标志物。
---
如需具体文献，建议在PubMed或Web of Science中以“NAPRT1 recombinant”/“NAPRT1 NAD”等关键词检索近年高引论文。
**Recombinant Human NAPRT1 Protein: Background**
Nicotinate phosphoribosyltransferase (NAPRT1) is a key enzyme involved in the biosynthesis of nicotinamide adenine dinucleotide (NAD+), an essential cofactor in cellular metabolism. It catalyzes the conversion of nicotinic acid (NA) to nicotinic acid mononucleotide (NAMN), a critical step in the Preiss-Handler pathway—one of the primary NAD+ salvage pathways. NAD+ plays a central role in redox reactions, energy production, DNA repair, and signaling processes, making NAPRT1 vital for maintaining cellular homeostasis.
Recombinant human NAPRT1 protein is produced using biotechnological methods, often expressed in *E. coli* or mammalian cell systems, followed by purification to ensure high activity and stability. Its recombinant form enables detailed studies of enzyme kinetics, structure-function relationships, and interactions with substrates or inhibitors. Research highlights its therapeutic potential, as NAD+ depletion is linked to aging, metabolic disorders, and neurodegenerative diseases. Additionally, NAPRT1 deficiency has been associated with certain cancers, where its loss may drive dependency on alternative NAD+ pathways, offering targets for precision therapies.
Studies leveraging recombinant NAPRT1 also explore its role in modulating inflammation and oxidative stress, further broadening its biomedical relevance. This protein serves as a tool for drug discovery, biomarker development, and understanding molecular mechanisms underlying NAD+-related pathologies.
×
